FNIP2 as a Radioligand Therapy Target
FNIP2, folliculin interacting protein 2, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, FNIP2 staining is highest in neuroendocrine tumors (100% of samples positive), liver cancer (100% of samples positive) and kidney cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is FNIP2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in neuroendocrine tumors, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
FNIP2 expression in cancer
Protein expression of FNIP2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Neuroendocrine Tumors | 0.83 | High | 100% |
| Liver Cancer | 0.72 | High | 100% |
| Kidney Cancer | 0.69 | High | 100% |
| Gastric Cancer | 0.69 | High | 92% |
| Testicular Cancer | 0.64 | High | 100% |
| Breast Cancer | 0.64 | High | 100% |
| Thyroid Cancer | 0.58 | High | 100% |
| Pancreatic Cancer | 0.58 | High | 92% |
| Colorectal Cancer | 0.58 | High | 100% |
| Ovarian Cancer | 0.56 | High | 89% |
| Head and Neck Cancer | 0.50 | Medium | 100% |
| Endometrial Cancer | 0.50 | Medium | 100% |
| Cervical Cancer | 0.50 | Medium | 90% |
| Bladder Cancer | 0.48 | Medium | 82% |
| Melanoma | 0.47 | Medium | 92% |
| Lymphoma | 0.47 | Medium | 83% |
| Prostate Cancer | 0.42 | Medium | 83% |
| Lung Cancer | 0.31 | Medium | 83% |
| Skin Cancer | 0.28 | Medium | 67% |
Not detected by IHC in: glioma.
Is FNIP2 internalized?
Nuclens has not yet extracted internalization evidence for FNIP2. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
FNIP2 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for FNIP2 yet. Search ClinicalTrials.gov for FNIP2 trials.
FNIP2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See FNIP2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
FNIP2 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.02 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related neuroendocrine tumors radioligand targets
HER3 (ERBB3) · c-MET (MET) · SSTR2 · STEAP2 · EPCAM · ITGB6 · KIT · FAP
See all radioligand therapy targets in neuroendocrine tumors.
See how FNIP2 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.